Orthocell Ltd ( (AU:OCC) ) has shared an update.
Orthocell Ltd reported record revenue for the third consecutive quarter, driven by the success of its Striate+ and Remplir products. The company achieved significant milestones, including regulatory approval for Remplir in Singapore, submission of a US FDA application, and preparation for its US commercial launch, supported by a $17 million placement and key executive appointments.
More about Orthocell Ltd
Orthocell Ltd is a company in the medical device industry, focusing on innovative products for nerve repair such as Striate+ and Remplir. The company is actively expanding its market reach with a focus on significant regions such as the USA, Singapore, and ASEAN.
YTD Price Performance: 1.48%
Average Trading Volume: 1,519,085
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$340.4M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.